Iovance Biotherapeutics, Inc.
http://www.iovance.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Iovance Biotherapeutics, Inc.
Adaptimmune Starts Planning TCR Commercialization For An Ultra Rare Patient Population
CEO Adrian Rawcliffe talked with Scrip about filing and early commercial plans for afami-cel in synovial carcinoma if it is approved by the FDA.
Iovance To Press Ahead With Melanoma Cell Therapy Filing Despite Doubters
Iovance has seen its share price collapse after releasing data from a second melanoma patient cohort – but is confident its potential first-in-class therapy is approvable.
Adaptimmune/Genentech Deal Gives Powerful Push To Solid Tumor Cell Therapies
Adaptimmune is getting a leg up in the race to develop iPSC-derived allogeneic cell therapies in a deal with the Roche subsidiary worth potentially more than $3bn.
Eight Oncology Drug Launches Expected In 2022 – Solid Tumors
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are eight new oncology products to treat solid tumors that could make their market debuts next year.
Company Information
- Industry
- Biotechnology
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Genesis Biopharma
- Lion Biotechnologies, Inc. (LBIO)